Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (346)	11/29/1999 10:12:00 PM
From: Miljenko Zuanic	Respond to of 1834

Rick, Yes, I did some extra work on NBIX, but... Credit to me, to you, or anyone else,... is it that important? As long as WE discuss bts and come to profitable conclusion like on NBIX, than every contributor bring value in ours success. BTW, thanks for note on yahoo NBIX tread. Guys, I will copy here. When Rick is writing it most be worth something. Right? << amateur? by: BioFreak2 11/29/1999 12:47 am EST Msg: 956 of 1047 You're talking about the widely regarded "best biotech investor of '99" (Dr. Zuanic) and the editor of the newsletter "Neuroinvestment" (Dr. Tracy). Before you go popping off your mouth, do some research.>> Many thanks, again. Back to NBIX. Insomnia data looks very good. Rapid onset and NO residual next day hangover effects is what make good sedation drug. Also, this was for transient insomnia pts. For chronic insomnia I am expecting much bigger difference between drug and placebo, or more robust results. 550 subjects in PII and 1500 in PIII? Geze, pharmas must be forming line ( partnership offer, what else) from Pinne Road all the way to Mexico border! CRF-R1 antagonist: medical relevant statistical significance was achieved. Can't wait for more data on this drug. :) Miljenko PS: My thanks to NBIX train too.